REPL · CIK 0001737953
What Replimune Group, Inc. told the SEC could break it.
Replimune is a pre-revenue biotech whose future rests on one product: it has never generated product revenue and may never be profitable, having funded itself with roughly $1.1 billion raised since its 2018 IPO, so it stays dependent on continued capital raises. Its prospects hinge on FDA approval of its single lead candidate, RP1 for advanced melanoma, which is currently under BLA review — a binary regulatory event for the company. A smaller, structural exposure is currency: because the majority of its R&D is performed through its Oxfordshire, UK subsidiary in British pounds, it carries GBP/USD foreign-exchange risk.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Other disclosures
- no product revenue; dependent on continued capital raisesmedium
Replimune has never generated product revenue and may never be profitable, having funded operations through ~$1.1B raised since its 2018 IPO.
“We have never generated any revenue from product sales and may never be profitable.”
SEC filing →As of 2025
Currency (FX)
- GBP exposure — majority of R&D in UK subsidiarylow
The majority of R&D costs are incurred in British pounds through Replimune's Oxfordshire, UK subsidiary, creating GBP/USD foreign-exchange exposure.
“The majority of our research and development costs are incurred by our subsidiary in Oxfordshire, United Kingdom, whose functional currency is the British pound.”
Regulatory & policy
- lead candidate RP1 dependent on FDA BLA approvallow
Replimune's prospects hinge on FDA approval of its single lead candidate, RP1 for advanced melanoma, which is under BLA review.
“Our lead product candidate, RP1, is the potential treatment of advanced melanoma, which is currently under BLA review with the FDA.”
SEC filing →As of 2025
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch